Z-drugs (zolpidem / eszopiclone / zaleplon)
Sleep & Recovery · GABA-A alpha-1 positive modulators
Tier B-
High-risk evidence profile
Bottom line
Read Off Label grades Z-drugs (zolpidem / eszopiclone / zaleplon) as B- (6.2/10) based on strong evidence, strong benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
FDA 2019 black-boxed complex sleep behaviors after deaths from sleep-driving/sleep-related activities.
Studied, labeled, or reported-use context: Zolpidem 5-10 mg; eszopiclone 1-3 mg; zaleplon 5-20 mg PO at bedtime — Rx; not individualized guidance.
What the evidence says
FDA 2019 black-boxed complex sleep behaviors after deaths from sleep-driving/sleep-related activities. Historically used chronically despite short-term approval. Tolerance develops within weeks; withdrawal insomnia returns upon discontinuation. Newer DORAs have a different adverse-effect and sleep-architecture profile; cost and access differ.
Mechanism
Preferentially bind GABA-A receptor alpha-1 subunit (vs benzodiazepines which bind multiple); shorter half-life; FDA-approved for short-term insomnia; 'complex sleep behaviors' black box
Studied, labeled, or reported dose & route
Zolpidem 5-10 mg; eszopiclone 1-3 mg; zaleplon 5-20 mg PO at bedtime
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Z-drugs (zolpidem / eszopiclone / zaleplon)'s effects?
- Read Off Label rates the evidence for Z-drugs (zolpidem / eszopiclone / zaleplon) as Strong and the benefit magnitude as strong, producing an overall grade of B- (6.2/10). FDA 2019 black-boxed complex sleep behaviors after deaths from sleep-driving/sleep-related activities.
- What safety findings are reported for Z-drugs (zolpidem / eszopiclone / zaleplon)?
- Z-drugs (zolpidem / eszopiclone / zaleplon) has a med-high risk profile in the database. Med-High (complex sleep behaviors — sleep-driving, sleep-eating with amnesia — FDA black box 2019; dependence and withdrawal; next-day impairment; fall/fracture risk in elderly; paradoxical agitation) Legal status: Rx (Schedule IV US).
- What does the low Safety score for Z-drugs (zolpidem / eszopiclone / zaleplon) represent?
- The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Z-drugs (zolpidem / eszopiclone / zaleplon)?
- Zolpidem 5-10 mg; eszopiclone 1-3 mg; zaleplon 5-20 mg PO at bedtime This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Z-drugs (zolpidem / eszopiclone / zaleplon) work?
- Preferentially bind GABA-A receptor alpha-1 subunit (vs benzodiazepines which bind multiple); shorter half-life; FDA-approved for short-term insomnia; 'complex sleep behaviors' black box
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.